Oral lichen planus: Update on etiopathogenesis, diagnosis and treatment

Immunopharmacology and Immunotoxicology

Volumn 33, Issue 1, 2011, Pages 11-20

  Crincoli, Vito ^a   Di Bisceglie, Maria Beatrice ^a   Scivetti, Michele ^a   Lucchese, Alberta ^a   Tecco, Simona ^b   Festa, Felice ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

biologics; Lichen planus; therapy

Indexed keywords

AMPHOTERICIN; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAMETHASONE VALERATE; CHLORHEXIDINE; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIN; FLUOCINOLONE ACETONIDE; GAMMA INTERFERON; GOLD SALT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; INTERLEUKIN 8; MICONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; NYSTATIN; ORAL ANTIDIABETIC AGENT; PENICILLAMINE; RETINOID; TACROLIMUS; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

BASAL CELL; CYTOKINE PRODUCTION; CYTOLYSIS; DERMOEPIDERMAL JUNCTION; DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LICHEN PLANUS; LICHENOID ERUPTION; MALIGNANT TRANSFORMATION; NONHUMAN; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW;

CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; LICHEN PLANUS, ORAL; MOUTH MUCOSA; MOUTH NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 79551605531     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2010.498014     Document Type: Review

References (96)

1. Setterfeld, J.F., Neill, S., Shirlaw, PJ., Teron, J., Vaughan, R., Escudier, M., Challacombe, S.J., Black, M.M. Te vulvovaginal gingival syndrome: a severe subgroup of lichen planus with characteristic clinical features and a novel association with the class II HLA DQB1*0201 allele. J. Am. Acad. Dermatol. 2006, 55, 98-113.
2. Quispel, R., van Boxel, O.S., Schipper, M.E., Sigurdsson, V, Canninga-van Dijk, M.R., Kerckhofs, A., Smout, AJ., Samsom, M., Schwartz, M.P. High prevalence of esophageal involvement in lichen planus: a study using magnifcation chromoendoscopy. Endoscopy 2009, 41, 187-193.
3. Torne, J.E., Jabs, D.A., Nikolskaia, O.V., Mimouni, D., Anhalt, G.J., Nousari, H.C. Lichen planus and cicatrizing conjunctivitis: char-acterization of fve cases. Am. J. Ophthalmol. 2003, 136, 239-243.
4. Mignogna, M.D., Lo Russo, L., Fedele, S. Gingival involvement of oral lichen planus in a series of 700 patients. J. Clin. Periodontol. 2005, 32, 1029-1033.
5. González Moles, M.A., Esteban, F., Ruiz-Avila, I., Gil Montoya, J.A., Brener, S., Bascones-Martínez, A., Muñoz, M. A role for the sub-stance P/NK-1 receptor complex in cell proliferation and apop-tosis in oral lichen planus. Oral Dis. 2009, 15, 162-169.
6. Pinholt, E.M., Rindum, J., Pindborg, J.J. Oral cancer: a retrospec-tive study of 100 Danish cases. Br. J. Oral Maxillofac Surg. 1997, 35, 77-80.
7. Ingafou, M., Leao, J.C., Porter, S.R., Scully, C. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis. 2006, 12, 463-468.
8. Bricker, S.L. Oral lichen planus: a review. Semin. Dermatol. 1994, 13, 87-90.
9. Torn, J.J., Holmstrup, P., Rindum, J., Pindborg, J.J. Course of vari-ous clinical forms of oral lichen planus. A prospective follow-up study of 611 patients. J. Oral Pathol. 1988, 17, 213-218.
10. Ismail, S.B., Kumar, S.K., Zain, R.B. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J. Oral Sci. 2007, 49, 89-106.
11. Al-Hashimi, I., Schifter, M., Lockhart, P.B., Wray, D., Brennan, M., Migliorati, C.A., Axéll, T., Bruce, A.J., Carpenter, W., Eisenberg, E., Epstein, J.B., Holmstrup, P., Jontell, M., Lozada-Nur, F., Nair, R., Silverman, B., Tongprasom, K., Tornhill, M., Warnakulasuriya, S., van der Waal, I. Oral lichen planus and oral lichenoid lesions: diag-nostic and therapeutic considerations. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2007, 103 Suppl, S25.e1-S25.12.
12. Tornhill, M.H., Pemberton, M.N., Simmons, R.K., Teaker, E.D. Amalgam-contact hypersensitivity lesions and oral lichen planus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003, 95, 291-299.
13. Carrozzo, M., Torpe, R. Oral lichen planus: a review. Minerva Stomatol. 2009, 58, 519-537.
14. Walsh, L.J., Savage, N.W., Ishii, T., Seymour, G.J. Immunopathogenesis of oral lichen planus. J. Oral Pathol. Med. 1990, 19, 389-396.
15. Carrozzo, M., Uboldi de Capei, M., Dametto, E., Fasano, M.E., Arduino, P., Broccoletti, R., Vezza, D., Rendine, S., Curtoni, E.S., Gandolfo, S. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J. Invest. Dermatol. 2004, 122, 87-94.
16. Fujita, H., Kobayashi, T., Tai, H., Nagata, M., Hoshina, H., Nishizawa, R., Takagi, R., Yoshie, H. Assessment of 14 functional gene polymorphisms in Japanese patients with oral lichen pla-nus: a pilot case-control study. Int. J. Oral Maxillofac Surg. 2009, 38, 978-983.
17. Bouma, G., Xia, B., Crusius, J.B., Bioque, G., Koutroubakis, I., Von Blomberg, B.M., Meuwissen, S.G., Peña, A.S. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with infammatory bowel disease (IBD). Clin. Exp. Immunol. 1996, 103, 391-396.
18. Simark-Mattsson, C, Bergenholtz, G., Jontell, M., Eklund, C, Seymour, G.J., Sugerman, P.B., Savage, N.W., Dahlgren, U.I. Distribution of interleukin-2,-4,-10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch. Oral Biol. 1999, 44, 499-507.
19. Carrozzo, M. Oral diseases associated with hepatitis C virus infec-tion. Part 2: lichen planus and other diseases. Oral Dis. 2008, 14, 217-228. (Pubitemid 351379714)
20. Carrozzo, M., Brancatello, F., Dametto, E., Arduino, P., Pentenero, M., Rendine, S., Porter, S.R., Lodi, G., Scully, C., Gandolfo, S. Hepatitis C virus-associated oral lichen planus: is the geographical heterogene-ity related to HLA-DR6? J. Oral Pathol. Med. 2005, 34, 204-208.
21. Wenzel, J., Scheler, M., Proelss, J., Bieber, T., Tüting, T. Type I interferon-associated cytotoxic infammation in lichen planus. J. Cutan. Pathol. 2006, 33, 672-678.
22. Rice, P.J., Hamburger, J. Oral lichenoid drug eruptions: their rec-ognition and management. Dent. Update 2002, 29, 442-447.
23. Van Der Meij, E.H., van der Waal, I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modi-fcations. J. Oral Pathol. Med. 2003, 32, 507-512.
24. Van Der Waal, I. Oral lichen planus and oral lichenoid lesions; a critical appraisal with emphasis on the diagnostic aspects.Med Oral Patol Oral Cir Bucal, 2009, 14, 310-314.
25. Eisenberg, E. Clinicopathologic patterns of oral lichenoid lesions. Oral Maxillofac Surg Clin North Am, 1994, 6, 445.
26. Mutasim, D.F., Adams, B.B. Immunofuorescence in dermatol-ogy. J. Am. Acad. Dermatol. 2001, 45, 803-22; quiz 822.
27. Helander, S.D., Rogers, R.S. 3rd. Te sensitivity and specifcity of direct immunofuorescence testing in disorders of mucous mem-branes. J. Am. Acad. Dermatol. 1994, 30, 65-75.
28. Kanokvalai, K, Sukhum, J., Supenya, V, Pinkaew S., Sutthipinittharm P. Direct immunofuorescence study in patients with lichen planus. Int J Dermatol, 2007, 46, 1237-1241.
29. Camisa, C, Nef, J.C., Olsen, R.G. Use of indirect immunofuo-rescence in the lupus erythematosus/lichen planus overlap syndrome: an additional diagnostic clue. J. Am. Acad. Dermatol. 1984, 11, 1050-1059.
30. Inaloz, H.S., Chowdhury, M.M.U., Motley, R.J. Scarring alopecia in LE/LP overlap syndrome: a case report. J Eur Acad Dermatol Venereol, 2000, 15, 171-174.
31. Rhodus, N.L., Cheng, B., Ondrey, F. T1/T2 cytokine ratio in tis-sue transudates from patients with oral lichen planus. Mediators Infamm. 2007, 2007, 19854.
32. Krutchkof, D.J., Cutler, L., Laskowski, S. Oral lichen planus: the evidence regarding potential malignant transformation. J. Oral Pathol. 1978, 7, 1-7.
33. Van Der Meij, E.H., Schepman, K.P., van der Waal, I. Te possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003, 96, 164-171.
34. Gandolfo, S., Richiardi, L., Carrozzo, M., Broccoletti, R., Carbone, M., Pagano, M., Vestita, C, Rosso, S., Merletti, F. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol. 2004, 40, 77-83.
35. Lanfranchi-Tizeira, H.E., Aguas, S.C., Sano, S.M. Malignant trans-formation of atypical oral lichen planus: a review of 32 cases. Med. Oral 2003, 8, 2-9.
36. Mignogna, M.D., Lo Muzio, L., Lo Russo, L., Fedele, S., Ruoppo, E., Bucci, E. Clinical guidelines in early detection of oral squamous cell carcinoma arising in oral lichen planus: a 5-year experience. Oral Oncol. 2001, 37, 262-267.
37. Lozada-Nur, F. Oral lichen planus and oral cancer: is there enough epidemiologic evidence? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2000, 89, 265-266.
38. Fatahzadeh, M., Rinaggio, J., Chiodo, T. Squamous cell carcinoma arising in an oral lichenoid lesion. J. Am. Dent. Assoc 2004, 135, 754-9; quiz 796.
39. Lo Muzio, L., Mignogna, M.D., Favia, G., Procaccini, M., Testa, N.F., Bucci, E. Te possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. Oral Oncol. 1998, 34, 239-246.
40. Mignogna, M.D., Lo Russo, L., Fedele, S., Ruoppo, E., Califano, L., Lo Muzio, L. Clinical behaviour of malignant transforming oral lichen planus. Eur. J. Surg. Oncol. 2002, 28, 838-843.
41. Markopoulos, A.K., Antoniades, D., Papanayotou, P., Trigonidis, G. Malignant potential of oral lichen planus; a follow-up study of 326 patients. Oral Oncol. 1997, 33, 263-269.
42. Mignogna, M.D., Fedele, S., Lo Russo, L., Mignogna, C, de Rosa, G., Porter, S.R. Field cancerization in oral lichen planus. Eur. J. Surg. Oncol. 2007, 33, 383-389.
43. Van Der Meij, E.H., Mast, H., van der Waal, I. Te possible pre-malignant character of oral lichen planus and oral lichenoid lesions: a prospective fve-year follow-up study of 192 patients. Oral Oncol. 2007, 43, 742-748.
44. Mattsson, U., Jontell, M., Holmstrup, P. Oral lichen planus and malignant transformation: is a recall of patients justifed? Crit. Rev. Oral Biol. Med. 2002, 13, 390-396.
45. Scully, C, Beyli, M., Ferreiro, M.C., Ficarra, G., Gill, Y., Grifths, M., Holmstrup, P., Mutlu, S., Porter, S., Wray, D. Update on oral lichen planus: etiopathogenesis and management. Crit. Rev. Oral Biol. Med. 1998, 9, 86-122.
46. Scully, C, Eisen, D., Carrozzo, M. Management of oral lichen planus. Am. J. Clin. Dermatol. 2000, 1, 287-306.
47. Tomson, M.A., Hamburger, J., Stewart, D.G., Lewis, H.M. Treatment of erosive oral lichen planus with topical tacrolimus. J. Dermatolog. Treat. 2004, 15, 308-314.
48. Byrd, J.A., Davis, M.D., Bruce, A.J., Drage, L.A., Rogers, R.S. 3rd. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch. Dermatol. 2004, 140, 1508-1512.
49. Branchet, M.C., Boisnic, S., Pascal, F., Ben Slama, L., Rostin, M., Szpirglas, H. [Topical tretinoin in the treatment of lichen pla-nus and leukoplakia of the oral mucosa. A biochemical evalua-tion of the keratinization]. Ann. Dermatol. Venereol. 1994, 121, 464-469.
50. Eisen, D. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial. J. Am. Acad. Dermatol. 1993, 28, 609-612.
51. Setterfeld, J.F., Black, M.M., Challacombe, S.J. Te management of oral lichen planus. Clin. Exp. Dermatol. 2000, 25, 176-182.
52. Plemons, J.M., Rees, T.D., Zachariah, N.Y. Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus. Oral Surg. Oral Med. Oral Pathol. 1990, 69, 688-693.
53. Vincent, S.D., Fotos, P.G., Baker, K.A., Williams, T.P. Oral lichen planus: the clinical, historical, and therapeutic features of 100 cases. Oral Surg. Oral Med. Oral Pathol. 1990, 70, 165-171.
54. Lozada-Nur, F., Huang, M.Z., Zhou, G.A. Open preliminary clini-cal trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg. Oral Med. Oral Pathol. 1991, 71, 283-287.
55. Mollaoglu, N. Oral lichen planus: a review. Br. J. Oral Maxillofac Surg. 2000, 38, 370-377.
56. Silverman, S. Jr, Gorsky, M., Lozada-Nur, F., Giannotti, K. A pro-spective study of fndings and management in 214 patients with oral lichen planus. Oral Surg. Oral Med. Oral Pathol. 1991, 72, 665-670.
57. Eisen, D. Te therapy of oral lichen planus. Crit. Rev. Oral Biol. Med. 1993, 4, 141-158.
58. Boisnic, S., Licu, D., Ben Slama, L., Branchet-Gumila, M.C., Szpirglas, H., Dupuy, P. Topical retinaldehyde treatment in oral lichen planus and leukoplakia. Int. J. Tissue React. 2002, 24, 123-130.
59. Buajeeb, W., Kraivaphan, P., Pobrurksa, C. Efcacy of topical retinoic acid compared with topical fuocinolone acetonide in the treatment of oral lichen planus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1997, 83, 21-25.
60. Eisen, D., Ellis, C.N., Duell, E.A., Grifths, C.E., Voorhees, J.J. Efect of topical cyclosporine rinse on oral lichen pla-nus. A double-blind analysis. N. Engl. J. Med. 1990, 323, 290-294.
61. Bécherel, P.A., Chosidow, O., Boisnic, S., Moyal-Barraco, M., Pelisse, M., Reigneau, O., Francès, C. Topical cyclosporine in the treatment of oral and vulvar erosive lichen planus: a blood level monitoring study. Arch. Dermatol. 1995, 131, 495-496.
62. Sieg, P., Von Domarus, H., Von Zitzewitz, V, Iven, H., Färber, L. Topical cyclosporin in oral lichen planus: a controlled, rand-omized, prospective trial. Br. J. Dermatol. 1995, 132, 790-794.
63. Ruzicka, T., Assmann, T., Homey, B. Tacrolimus: the drug for the turn of the millennium? Arch. Dermatol. 1999, 135, 574-580.
64. Böhm, M., Beissert, S., Schwarz, T., Metze, D., Luger, T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997, 349, 541.
65. Grundmann-Kollmann, M., Podda, M., Ochsendorf, F., Boehncke, W.H., Kaufmann, R., Zollner, T.M. Mycophenolate mofetil is efective in the treatment of atopic dermatitis. Arch. Dermatol. 2001, 137, 870-873. (Pubitemid 32641646)
66. Basara, N., Blau, W.I., Kiehl, M.G., Römer, E., Rudolphi, M., Bischof, M., Kirsten, D., Sanchez, H., Günzelmann, S., Fauser, A.A. Efcacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant. Proc 1998, 30, 4087-4089. (Pubitemid 29013165)
67. Nousari, H.C., Goyal, S., Anhalt, G.J. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophe-nolate mofetil. Arch. Dermatol. 1999, 135, 1420-1421.
68. Frieling, U., Bonsmann, G., Schwarz, T., Luger, T.A., Beissert, S. Treatment of severe lichen planus with mycophenolate mofetil. J. Am. Acad. Dermatol. 2003, 49, 1063-1066.
69. Nylander Lundqvist, E., Wahlin, Y.B., Hofer, P.A. Methotrexate supplemented with steroid ointments for the treatment of severe erosive lichen ruber. Acta Derm. Venereol. 2002, 82, 63-64.
70. Rozycki, T.W., Rogers, R.S. 3rd, Pittelkow, M.R., McEvoy, M.T., el-Azhary, R.A., Bruce, A.J., Fiore, J.P., Davis, M.D. Topical tac-rolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J. Am. Acad. Dermatol. 2002, 46, 27-34.
71. Ruzicka, T., Bieber, T., Schöpf, E., Rubins, A., Dobozy, A., Bos, J.D., Jablonska, S., Ahmed, I., Testrup-Pedersen, K., Daniel, F., Finzi, A., Reitamo, S. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N. Engl. J. Med. 1997, 337, 816-821.
72. Fung, J.J., Todo, S., Tzakis, A., Demetris, A., Jain, A., Abu-Elmaged, K., Alessiani, M., Starzl, T.E. Conversion of liver allograft recipients from cyclosporine to FK 506-based immu-nosuppression: benefts and pitfalls. Transplant. Proc 1991, 23, 14-21.
73. Kelly, P.A., Burckart, G.J., Venkataramanan, R. Tacrolimus: a new immunosuppressive agent. Am. J. Health. Syst. Pharm. 1995, 52, 1521-1535.
74. Meingassner, J.G., Stütz, A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J. Invest. Dermatol. 1992, 98, 851-855.
75. Aoyama, H., Tabata, N., Tanaka, M., Uesugi, Y., Tagami, H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br. J. Dermatol. 1995, 133, 494-496.
76. Vente, C., Reich, K., Rupprecht, R., Neumann, C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br. J. Dermatol. 1999, 140, 338-342.
77. Reich, K., Vente, C, Neumann, C. Topical tacrolimus for pyo-derma gangrenosum. Br. J. Dermatol. 1998, 139, 755-757.
78. Kaliakatsou, F., Hodgson, T.A., Lewsey, J.D., Hegarty, A.M., Murphy, A.G., Porter, S.R. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J. Am. Acad. Dermatol. 2002, 46, 35-41.
79. US Food and Drug Administration: FDA Public Health Advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. 3-10-2005.
80. Becker, J.C., Houben, R., Vetter, C.S., Bröcker, E.B. Te carci-nogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006, 6, 7.
81. Swift, J.C., Rees, T.D., Plemons, J.M., Hallmon, W.W., Wright, J.C. Te efectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J. Periodontol. 2005, 76, 627-635.
82. Passeron, T., Lacour, J.P., Fontas, E., Ortonne, J.P. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pime-crolimus levels in the blood. Arch. Dermatol. 2007, 143, 472-476.
83. Volz, T., Caroli, U., Lüdtke, H., Bräutigam, M., Kohler-Späth, H., Röcken, M., Biedermann, T. Pimecrolimus cream 1% in erosive oral lichen planus-a prospective randomized double-blind vehicle-controlled study. Br. J. Dermatol. 2008, 159, 936-941.
84. Soria, A., Agbo-Godeau, S., Taïeb, A., Francès, C. Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases. Dermatology (Basel). 2009, 218, 22-25.
85. Cheng, A., Mann, C. Oral erosive lichen planus treated with efali-zumab. Arch. Dermatol. 2006, 142, 680-682.
86. rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005, New Orleans, La.
87. Connolly, M., Armstrong, J.S., Buckley, D.A. Infiximab treat-ment for severe orogenital ulceration in Behçet's disease. Br. J. Dermatol. 2005, 153, 1073-1075.
88. Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis, 2000, 59 Suppl 1, 146-149.
89. Yarom, N. Etanercept for the management of oral lichen planus. Am. J. Clin. Dermatol. 2007, 8, 121.
90. Fivenson, D.P., Mathes, B. Treatment of generalized lichen planus with alefacept. Arch. Dermatol. 2006, 142, 151-152.
91. Chamian, F., Lin, S.L., Lee, E., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M., Cardinale, I., Khatcherian, A., Novitskaya, I., Wittkowski, K.M., Krueger, J.G., Lowes, M.A. Alefacept (anti-CD2) causes a selective reduction in circulating efector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med, 2007, 7, 5-27.
92. Grillo-López, AJ. Rituximab: an insider's historical perspective. Semin. Oncol. 2000, 27, 9-16.
93. Cooper, H.L., Healy, E., Teaker, J.M., Friedmann, P.S. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin. Exp. Dermatol. 2003, 28, 366-368.
94. Barnadas, M., Roe, E., Brunet, S., Garcia, P., Bergua, P., Pimentel, L., Puig, L., Francia, A., García, R., Gelpí, C, Sierra, J., Coll, P., Alomar, A. Terapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 69-74.
95. Cutler, C, Miklos, D., Kim, H.T., Treister, N., Woo, S.B., Bienfang, D., Klickstein, L.B., Levin, J., Miller, K., Reynolds, C, Macdonell, R., Pasek, M., Lee, S.J., Ho, V., Soifer, R., Antin, J.H., Ritz, J., Alyea, E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108, 756-762. (Pubitemid 44061381)
96. Salopek, T.G., Logsetty, S., Tredget, E.E. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalci-trant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J. Am. Acad. Dermatol. 2002, 47, 785-788.